#1 Clinical Trials Search in Europe

Tapderimotide

Tapderimotide, a component of the UV1 vaccine, is currently being studied in clinical trials for its potential in treating various types of cancer, including non-small cell lung cancer, malignant pleural mesothelioma, and ovarian cancer. This article explores the ongoing research and potential benefits of Tapderimotide in cancer treatment.

Table of Contents

What is TAPDERIMOTIDE?

TAPDERIMOTIDE is an experimental cancer vaccine that is currently being studied in clinical trials[1]. It is part of a therapeutic cancer vaccine called UV1, which also contains two other active substances: alrefimotide and riletamotide[2]. These substances are proteins designed to stimulate the immune system to fight cancer cells.

How does TAPDERIMOTIDE work?

As a cancer vaccine, TAPDERIMOTIDE works by activating the body’s immune system to recognize and attack cancer cells. It is designed to target specific proteins found on cancer cells, helping the immune system identify and destroy them more effectively[1]. This approach is part of a growing field called immunotherapy, which harnesses the power of the body’s own defense mechanisms to fight cancer.

What types of cancers is TAPDERIMOTIDE being studied for?

TAPDERIMOTIDE is currently being investigated for several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is a type of lung cancer that accounts for about 80-85% of all lung cancers[1].
  • Malignant pleural mesothelioma (MPM): This is a rare and aggressive cancer that affects the lining of the lungs (pleura)[2].
  • Ovarian cancer: Specifically, it’s being studied in patients with recurrent ovarian cancer who do not have a BRCA mutation[3].

Current Clinical Trials

TAPDERIMOTIDE is being evaluated in several clinical trials:

  1. NSCLC Trial: This is a phase II study investigating the efficacy and safety of UV1 vaccine with or without sargramostim for patients with advanced or metastatic non-small cell lung cancer[1].
  2. Mesothelioma Trial (NIPU-study): This study is evaluating nivolumab and ipilimumab with or without UV1 vaccination as second-line treatment in patients with malignant mesothelioma[2].
  3. Ovarian Cancer Trial: This is a randomized clinical trial investigating olaparib, durvalumab, and UV1 as maintenance therapy in patients with recurrent ovarian cancer without BRCA mutation[3].

These trials aim to determine how effective TAPDERIMOTIDE is in treating these cancers, either alone or in combination with other treatments.

How is TAPDERIMOTIDE administered?

TAPDERIMOTIDE is administered as a powder for solution for injection. It is given through intradermal use, which means it’s injected into the skin[1][2][3]. The typical dose is 300 micrograms, but the total amount and frequency may vary depending on the specific trial and treatment plan.

Potential Side Effects

As TAPDERIMOTIDE is still in clinical trials, the full range of potential side effects is not yet known. However, as with any medical treatment, patients should be aware that side effects may occur. Common side effects of cancer vaccines can include:

  • Injection site reactions (redness, swelling, pain)
  • Flu-like symptoms (fever, chills, fatigue)
  • Nausea
  • Headache

It’s important to note that the clinical trials are closely monitoring patients for any adverse effects to ensure safety[1][2][3].

Future Prospects

TAPDERIMOTIDE, as part of the UV1 vaccine, shows promise in the field of cancer immunotherapy. If the ongoing clinical trials demonstrate positive results, it could potentially become an important treatment option for patients with various types of cancer. However, it’s important to remember that the drug is still in the experimental stage, and more research is needed to fully understand its efficacy and safety profile.

Patients interested in learning more about TAPDERIMOTIDE or potentially participating in clinical trials should discuss this with their healthcare provider. They can provide more information and determine if it might be a suitable option based on individual circumstances.

Aspect Details
Drug Name Tapderimotide (component of UV1 vaccine)
Cancer Types Studied Non-small cell lung cancer, Malignant pleural mesothelioma, Ovarian cancer
Administration Method Intradermal injection
Main Study Objectives Efficacy and safety evaluation in combination with other treatments
Key Endpoints Progression-free survival, Overall survival, Objective response rate, Disease control rate
Patient Eligibility Varies by study; generally includes specific cancer types, stages, and previous treatment history
Combination Therapies Often studied with immunotherapy drugs (e.g., PD-1/PD-L1 inhibitors)

FAQ

  • What is Tapderimotide? Tapderimotide is one of the active substances in the UV1 vaccine, which is being studied for its potential to treat various types of cancer.
  • What types of cancer are being studied with Tapderimotide? Clinical trials are investigating Tapderimotide for non-small cell lung cancer, malignant pleural mesothelioma, and ovarian cancer.
  • How is Tapderimotide administered? Tapderimotide is administered as part of the UV1 vaccine through intradermal injection, which means it's injected just beneath the skin.
  • What are the main objectives of the clinical trials involving Tapderimotide? The main objectives include evaluating the efficacy and safety of UV1 vaccination in combination with other cancer treatments, such as immunotherapy drugs.
  • Are there any known side effects of Tapderimotide? The clinical trials are ongoing, and part of their purpose is to determine the safety and potential side effects of Tapderimotide. Specific side effects are not mentioned in the provided information.

Ongoing Clinical Trials on Tapderimotide

  • Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium Denmark Finland Germany Lithuania +3

  • Study of Nivolumab, Ipilimumab, and UV1 Vaccine for Patients with Malignant Pleural Mesothelioma After Initial Chemotherapy

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Norway Spain Sweden

  • Study on the Effectiveness and Safety of UV1 Vaccine with or without Sargramostim for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1
    Investigated drugs:
    Norway

Glossary

  • Tapderimotide: An active substance in the UV1 vaccine being studied for cancer treatment.
  • UV1 vaccine: A cancer vaccine containing Tapderimotide and other substances, currently being tested in clinical trials.
  • Non-small cell lung cancer (NSCLC): A type of lung cancer that is being studied in clinical trials with UV1 vaccine.
  • Malignant pleural mesothelioma (MPM): A type of cancer that affects the lining of the lungs, being investigated in trials with UV1 vaccine.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease control rate (DCR): The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, and stable disease.
  • Intradermal injection: A method of delivering a substance just beneath the skin.
  • ECOG performance status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer.
  • PD-1/PD-L1 inhibitor: A type of drug that helps the immune system recognize and attack cancer cells.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-uv1-vaccine-with-or-without-sargramostim-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer/
  2. http://clinicaltrials.eu/trial/study-of-nivolumab-ipilimumab-and-uv1-vaccine-for-patients-with-malignant-pleural-mesothelioma-after-initial-chemotherapy/
  3. http://clinicaltrials.eu/trial/study-on-olaparib-durvalumab-and-uv1-for-maintenance-therapy-in-patients-with-recurrent-ovarian-cancer-without-brca-mutation/